“mPAL” (Mobile Personalized Assessment and Learning), combines mHealth-based educational functions with the Ecological Momentary Assessment (EMA) functions of TED (transactional electronic diary) software. mPAL allows interchange of data obtained from EMA and learning system in order to deliver context-aware intervention in real time, customized to the individual needs of participants. mPAL enables participants to interact with educational materials at the time and place of their choosing and receive personalized feedback when and where it is most needed. The software integrates into HuRIS where comprehensive patient data can be leveraged alongside the mPAL data to provide better understanding of the underlying factors under investigation.

Potential Commercial Applications:
- Substance abuse
- Drug abuse
- Alcoholism
- Behavioral modification
- Smoking cessation
- Pain management

Competitive Advantages:
- Low-cost mobile treatment mechanism
- Provides personalized feedback to patients at the time and place they choose
- Proven usability in prior clinical studies

Development Stage:
Clinical
Massoud R. Vahabzadeh, Mustapha Mezghanni, and Jia-Ling Lin (all of NIDA)

Publications:


Licensing Contact: Michael Shmilovich; 301–435–5019; shmilovm@mail.nih.gov

Collaborative Research Opportunity: The NIDA, IRP, Biomedical Informatics Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Mobile Personalized Assessment & Learning for Addiction Treatment and Behavioral Modification. For collaboration opportunities, please contact Vio Conley at conleyv@mail.nih.gov.

Plasmid Useful in Transplantation Therapy for Age-Related Eye Disease

Description of Technology:
Researchers have developed a green fluorescent protein (GFP) based plasmid that can be used to detect differentiated retinal pigment epithelium (RPE) cells. RPE is a layer of cells located behind the eye that becomes damaged in age-related macular degeneration (AMD). Current cell based therapies for treating AMD focus on generating RPE cells from stem cells. This GFP-based plasmid can be inserted into growing stem cells, and the fluorescence marker can be used to detect and purify stem cells differentiating into RPE cells. This advancement allows generation of a purified population of RPE cells for in vitro and transplantation purposes.

Additionally, cells comprising the GFP-based construct may be useful in high-throughput drug screening as a means to: (1) identify potential therapeutic targets of RPE degenerative diseases such as AMD, and (2) evaluate initial toxicity of candidate drugs in RPE cells.

Potential Commercial Applications:
- Fluorescence based marker for detecting and purifying differentiated RPE cells
- Potential use in high throughput drug screening

Competitive Advantages: GFP based marker allows for fast and simple detection of differentiated RPE cells from stem cells.

Development Stage:
- Prototype
- In vitro data available

Inventors: Kapil Bharti (NINDS), Heinz Hrheiter (NINDS), Sheldon Millier (NEI)


Licensing Contact: Lauren Nguyen-Antczak, Ph.D., J.D.; 301–435–4074; lauren.nguyen-antczak@nih.gov.
notice at least 10 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments and if accepted by the committee, presentations may be limited to five minutes. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: http://www.nimh.nih.gov/about/advisory-boards-and-groups/namhc/index.shtml, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award: 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: August 8, 2012.

Anna P. Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the National Advisory Neurological Disorders and Stroke Council.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Translational Research Review.
Date: August 23, 2012.
Time: 4:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).
Contact Person: Ernest W. Lyons, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS, MSC 9529, Bethesda, MD 20892–9529, 301–496–4056, Lyons@ninds.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: August 8, 2012.

Anna P. Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the National Advisory Neurological Disorders and Stroke Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Neurological Disorders and Stroke Council.
Date: September 20–21, 2012.
Open: September 20, 2012, 8 a.m. to 2:15 P.M.
Agenda: Report by the Director, NINDS; Report by the Associate Director for Extramural Research; and Administrative and Program Developments.
Place: National Institutes of Health, Building 31, 31 Center Drive, C Wing, Conference Room 6, Bethesda, MD 20892.
Closed: September 20, 2012, 2:15 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 31, 31 Center Drive, C Wing, Conference Room 6, Bethesda, MD 20892.
Closed: September 21, 2012, 8 a.m. to 11 a.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 31, 31 Center Drive, C Wing, Conference Room 6, Bethesda, MD 20892.
Contact Person: Robert Finkelstein, Ph.D., Associate Director for Extramural Research, National Institute of Neurological Disorders and Stroke, NIH, 6001 Executive Blvd., Suite 3309, MSC 9531, Bethesda, MD 20892, (301) 496–9248.
Any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit.

Information is also available on the Institute’s/Center’s home page: http://www.ninds.nih.gov, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS).

Dated: August 8, 2012.

Anna P. Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.